Outlook Therapeutics Inc (OTLK) Stock Price, Quote & News

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company wa...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 619 3990

Website: www.outlooktherapeutics.com

Address:

111 S. Wood Avenue, Unit #100, Iselin, United States

FlyGurl Aug. 20 at 4:25 PM

$OTLK The list of reasons this gets approved is substantially longer than the reasons it won’t. I’m holding the line.

0 · Reply

SilentJoker34 Aug. 20 at 4:23 PM

$OTLK Booooom 🍻🇺🇸 Added 100 Bringing my total to 1000 @ $2.91

0 · Reply

Keekster1 Aug. 20 at 4:22 PM

$OTLK added 2K shares at 2.34

1 · Reply

Mystsylph Aug. 20 at 4:18 PM

$OTLK back in late aug 2023 when $OTLK got the crl its market cap was ~$350–400m even after rejection. today it’s sitting closer to ~$100–120m despite having the same drug, same indication, and arguably a cleaner resubmission (resolved cmc / inspection issues, no new safety red flags).

1 · Reply

The_Scientist Aug. 20 at 4:17 PM

$OTLK wish more people appreciate this

1 · Reply

DuckDagobert Aug. 20 at 4:14 PM

$OTLK Whats going on❔️❓️❔️❓️

1 · Reply

25_usa Aug. 20 at 4:10 PM

$OTLK It's clear that new institutional investors are shorting the stock, but they'll likely accumulate shares by the end of the day.

1 · Reply

flyinghollaender Aug. 20 at 4:06 PM

$OTLK bought again

0 · Reply

stockbug2k Aug. 20 at 4:02 PM

$OTLK Why panic? Do you need the money today? if so then you should not be invested

0 · Reply

Crazyhorse6 Aug. 20 at 4:01 PM

$OTLK while most retail is afraid I only accumulate!!

1 · Reply

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Jul 24, 2025, 9:00 AM EDT - 27 days ago

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Jul 22, 2025, 8:45 AM EDT - 4 weeks ago

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 1, 2025, 8:05 AM EDT - 7 weeks ago

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Jun 18, 2025, 9:05 AM EDT - 2 months ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Jun 10, 2025, 8:05 AM EDT - 2 months ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 2, 2025, 7:00 AM EDT - 2 months ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

May 23, 2025, 6:30 AM EDT - 3 months ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

May 22, 2025, 4:01 PM EDT - 3 months ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

May 15, 2025, 4:01 PM EDT - 3 months ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Apr 8, 2025, 8:45 AM EDT - 4 months ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Feb 28, 2025, 8:05 AM EST - 6 months ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 19, 2025, 9:00 AM EST - 6 months ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 14, 2025, 8:05 AM EST - 6 months ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Feb 4, 2025, 9:05 AM EST - 7 months ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Jan 31, 2025, 8:05 AM EST - 7 months ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Jan 23, 2025, 9:05 AM EST - 7 months ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 22, 2025, 9:05 AM EST - 7 months ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 16, 2025, 12:09 PM EST - 7 months ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

NVS

Jan 16, 2025, 6:00 AM EST - 7 months ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Jan 6, 2025, 7:19 AM EST - 8 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

INO RCKT

Dec 27, 2024, 8:05 AM EST - 8 months ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Dec 13, 2024, 4:30 PM EST - 8 months ago

Outlook Therapeutics® Streamlines Operations

Dec 4, 2024, 8:05 AM EST - 9 months ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Dec 3, 2024, 4:30 PM EST - 9 months ago

Outlook Therapeutics® Announces Executive Leadership Transition

Nov 27, 2024, 9:27 AM EST - 9 months ago

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Nov 27, 2024, 6:50 AM EST - 9 months ago

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Nov 6, 2024, 8:05 AM EST - 10 months ago

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Sep 16, 2024, 8:05 AM EDT - 1 year ago

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Sep 13, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Sep 4, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Sep 3, 2024, 8:45 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:11 AM EDT - 1 year ago

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles

AMD

Aug 14, 2024, 12:02 PM EDT - 1 year ago

Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript

Aug 14, 2024, 7:05 AM EDT - 1 year ago

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

Aug 12, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 7, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

Jul 30, 2024, 9:10 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

Jul 8, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 13, 2024, 5:22 PM EDT - 1 year ago

Outlook Therapeutics: Worth A Good Strong Look After CRL

Jun 13, 2024, 5:50 AM EDT - 1 year ago

Outlook Therapeutics: Speculative Buy With High Stakes In The Anti-VEGF Market

Jun 12, 2024, 10:00 AM EDT - 1 year ago

Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series

Jun 11, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

Jun 6, 2024, 10:30 AM EDT - 1 year ago

Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

May 28, 2024, 8:05 AM EDT - 1 year ago

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

May 16, 2024, 2:35 PM EDT - 1 year ago

Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript

May 15, 2024, 5:00 PM EDT - 1 year ago

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

May 13, 2024, 8:50 AM EDT - 1 year ago

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

FlyGurl Aug. 20 at 4:25 PM

$OTLK The list of reasons this gets approved is substantially longer than the reasons it won’t. I’m holding the line.

0 · Reply

SilentJoker34 Aug. 20 at 4:23 PM

$OTLK Booooom 🍻🇺🇸 Added 100 Bringing my total to 1000 @ $2.91

0 · Reply

Keekster1 Aug. 20 at 4:22 PM

$OTLK added 2K shares at 2.34

1 · Reply

Mystsylph Aug. 20 at 4:18 PM

1 · Reply

The_Scientist Aug. 20 at 4:17 PM

$OTLK wish more people appreciate this

1 · Reply

DuckDagobert Aug. 20 at 4:14 PM

$OTLK Whats going on❔️❓️❔️❓️

1 · Reply

25_usa Aug. 20 at 4:10 PM

$OTLK It's clear that new institutional investors are shorting the stock, but they'll likely accumulate shares by the end of the day.

1 · Reply

flyinghollaender Aug. 20 at 4:06 PM

$OTLK bought again

0 · Reply

stockbug2k Aug. 20 at 4:02 PM

$OTLK Why panic? Do you need the money today? if so then you should not be invested

0 · Reply

Crazyhorse6 Aug. 20 at 4:01 PM

$OTLK while most retail is afraid I only accumulate!!

1 · Reply

Ketchup17_ Aug. 20 at 3:56 PM

$OTLK need that 5+ million volume back

0 · Reply

Ketchup17_ Aug. 20 at 3:56 PM

$OTLK what’s happening

1 · Reply

TwongStocks Aug. 20 at 3:48 PM

Upcoming PDUFAs: $IONS with a PDUFA date of Aug 21 (tomorrow). For Donidalorsen as a HAE treatment. $OTLK with a PDUFA date of Aug 27. For LYTENAVA as a wet AMD treatment $TLX also has a Aug 27 PDUFA. For ZIRCAIX as a kidney cancer imaging agent.

0 · Reply

CliffordCapital Aug. 20 at 3:43 PM

$OTLK Need to break 2.39$! Come on 🫶🏼

1 · Reply

Britbox Aug. 20 at 3:42 PM

$OTLK I have 31,322 shares now Thank you for your cheapies those who got scared out

0 · Reply

NxtBgThng Aug. 20 at 3:42 PM

$OTLK Whole market is making a u-turn right now. Algos starting to go the other way now that everyone is panicking a little bit

0 · Reply

SteelerJon Aug. 20 at 3:39 PM

$OTLK I hope like hell you are short and get ripped twice…you are by far the biggest pain in the a$$ in here. 😎🏦🏦

1 · Reply

Mystsylph Aug. 20 at 3:39 PM

$OTLK people scared after the crash but this is when you wanna risk it for the biscuit. Once overall market looks bullish people will have confidence to add back to the riskier picks and this will skyrocket above 3

1 · Reply

NxtBgThng Aug. 20 at 3:39 PM

$OTLK Loading up on the 9/19 $2.50 call options at $45 per lot. Breakeven is $2.95... I like those odds

0 · Reply

25_usa Aug. 20 at 3:37 PM

$OTLK get in get in guys . Let’s add more liquidity.

0 · Reply

adayxs Aug. 20 at 3:31 PM

$OTLK I realize any answer to this would be speculation. Why would you be seeing huge hit jobs on this company now?

0 · Reply

NxtBgThng Aug. 20 at 3:31 PM

$OTLK Up 20% in the past week. Not bad.

1 · Reply

Market Cap	92.98M
Revenue (ttm)	0.00
Net Income (ttm)	-75.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.38

Volume	2,358,400
Avg Vol	1,112,016
Day's Range	N/A - N/A
Shares Out	33.57M
Stochastic %K	68%
Beta	0.26
Analysts	Strong Sell
Price Target	$9.00